Jenny M H Chen

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Venues

Advances in therapy

Leukemia & lymphoma

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Advances in therapy 41 (5) (2024)
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Advances in therapy 41 (5) (2024)
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Advances in therapy (2024)
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Advances in therapy 41 (5) (2024)
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sally W Wade, Ana Nunes, Chaoling Feng, Ioana Kloos, Weimin Peng, Julia T Snider, Dylan Maciel, Keith Chan, Sam Keeping, Bijal Shah
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. Advances in therapy 41 (5) (2024)
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M H Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez-Ubieto, Luca Fischer, Toby A Eyre, Sam Keeping, Julie E Park, James J Wu, Ana Nunes, John Reitan, Sally W Wade, Gilles Salles
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Leukemia & lymphoma (2023)
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M H Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jiménez-Ubie, Luca Fischer, Toby Andrew Eyre, Sam Keeping, Julie E Park, James J Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. British journal of haematology (2022)

Jenny M H Chen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jenny M H Chen